175 related articles for article (PubMed ID: 12798720)
1. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
Markman M; Zanotti K; Kulp B; Peterson G; Markman M
Gynecol Oncol; 2003 Jun; 89(3):514-6. PubMed ID: 12798720
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
4. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
[TBL] [Abstract][Full Text] [Related]
5. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Markman M; Zanotti K; Peterson G; Kulp B; Webster K; Belinson J
J Clin Oncol; 2003 Dec; 21(24):4611-4. PubMed ID: 14673050
[TBL] [Abstract][Full Text] [Related]
6. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
7. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
8. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
10. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.
McAlpine JN; Kelly MG; O'malley DM; Azodi M; Coombe K; Schwartz PE; Rutherford TJ
Gynecol Oncol; 2006 Oct; 103(1):288-92. PubMed ID: 16647749
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer.
Iwamoto T; Yuta A; Tabata T; Sugimoto H; Gabazza EC; Hirai H; Kojima S; Okuda M
Biol Pharm Bull; 2012; 35(9):1487-95. PubMed ID: 22975499
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Wu HL
J Oncol Pharm Pract; 2019 Sep; 25(6):1388-1395. PubMed ID: 30176784
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.
Zanotti KM; Rybicki LA; Kennedy AW; Belinson JL; Webster KD; Kulp B; Peterson G; Markman M
J Clin Oncol; 2001 Jun; 19(12):3126-9. PubMed ID: 11408510
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-related hypersensitivity reaction in Japanese patients with gynecologic malignancy.
Kitada K; Hashiguchi Y; Fukuda T; Yoshida H; Ichimura T; Matsumoto Y; Yasui T; Sumi T; Ishiko O
Eur J Gynaecol Oncol; 2012; 33(3):252-4. PubMed ID: 22873092
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M; Hsieh F; Zanotti K; Webster K; Peterson G; Kulp B; Spicel A; Belinson J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):25-8. PubMed ID: 14564516
[TBL] [Abstract][Full Text] [Related]
17. Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors.
Ma X; Li X
Int J Clin Oncol; 2018 Dec; 23(6):1160-1166. PubMed ID: 30078140
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Jones R; Ryan M; Friedlander M
Gynecol Oncol; 2003 Apr; 89(1):112-5. PubMed ID: 12694663
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin hypersensitivity.
Sliesoraitis S; Chikhale PJ
Int J Gynecol Cancer; 2005; 15(1):13-8. PubMed ID: 15670291
[TBL] [Abstract][Full Text] [Related]
20. A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms.
Piovano E; Pivetta E; Modaffari P; Martra F; Baima Poma C; Perotto S; Tripodi E; Zanfagnin V; Zola P; Ferrero A
Gynecol Obstet Invest; 2012; 74(1):21-7. PubMed ID: 22652565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
